4.3 Review

EBV and MS: Major cause, minor contribution or red -herring?

期刊

MULTIPLE SCLEROSIS AND RELATED DISORDERS
卷 16, 期 -, 页码 24-30

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2017.06.002

关键词

Epstein-Barr Virus (EBV); Multiple Sclerosis (MS); Environmental risk factors; Infectious Mononucleosis (IM); Molecular mimicry; MS pathogenesis

资金

  1. Bayer Health Care
  2. Biogen
  3. Genzyme Sanofi
  4. Merck
  5. Novartis
  6. TEVA

向作者/读者索取更多资源

Multiple Sclerosis (MS) is a chronic neurological disease with genetic and environmental risk factors. Epstein Barr-Virus (EBV) has been closely associated with MS but with a significant amount of conflicting evidence. Some of the evidence for EBV involvement in MS includes: almost 100% of MS patients showing past EBV infection, an association with Infectious Mononucleosis (acute EBV infection), higher titres of EBV antibodies associated with an increased risk of MS development, and an overall altered immune response to EBV found in peripheral blood and the CNS of MS patients. However, evidence for EBV presence in the CSF and T cell responses to EBV in MS have been particularly conflicting. Several hypotheses have been proposed for direct and indirect EBV involvement in MS such as 1) Molecular Mimicry 2) Mistaken Self 3) Bystander Damage and 4) Autoreactive B cells infected with EBV. More recently, an association between EBV and human endogenous retrovirus in MS has been shown, which may provide an alternative pathogenetic target for MS treatment. However, if EBV is not the major contributor to MS and is instead one of several viral or infectious agents able to elicit a similar altered immune response, MS development may be the result of a failure of viral clearance in general. This review aims to evaluate the evidence for the currently discussed theories of EBV involvement in MS pathogenesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据